The increase in price target by UBS suggests that the analyst sees some potential for stock price appreciation, despite maintaining a Neutral stance. This could lead to a positive short-term impact on ResMed's stock as investors may interpret the raised target as a sign of underlying value. However, since the rating remains Neutral, the impact may not be as significant as it would be with an upgrade to a Buy rating.